The prevalence of proteinuria at 1 year after renal transplantation ranges between 11% and
45% and is even higher in patients treated with inhibitors of the mammalian target of …

Background: A growing body of evidence suggests that everolimus might offer effective
immunosuppressive activity together with antiproliferative effects that may address some of …

Methods. Patients continued on P/CsA, P/MPS, or P and everolimus (EVL). Before
withdrawal, a transplant biopsy was performed ensuring no subclinical rejection was …

1E10, 101M; AAV-ASPA, agomelatine, aliskiren fumarate, alvimopan hydrate, ambrisentan,
apaziquone, axitinib; Becatecarin, belagenpumatucel-L, BMS-201038; Cannabidiol …

Calcineurin inhibitor drugs (CNI) are the mainstay of modern immunosuppression in renal
transplantation. However, they contribute significantly to the chronic loss of renal grafts and …

Introduction: Immunosuppressive drugs have a narrow therapeutic range and large inter-
individual response variability. This has prompted pharmacogenetic studies, mostly with …

The goal of this study was to assess the interaction of the mTOR inhibitors (ImTORs)
sirolimus and everolimus with the human organic anion-transporting polypeptides (OATPs) …

Epailly E, Albanell J, Andreassen A, Bara C, Campistol JM, Delgado JF, Eisen H, Fiane AE,
Mohacsi P, Schubert S, Sebbag L, Turazza FM, Valantine H, Zuckermann A, Potena L …

The aim of this study was to document the in vivo transport of everolimus (inhibitor of mTOR)
by P-glycoprotein (P-gp), and to investigate the influence of lapatinib (inhibitor of P-gp) on …

A series of recent meetings brought together experts in the field of transplantation to discuss
the challenge of improving long-term outcomes and establishing optimal strategies for …